Epibiotech Co., Ltd. (XKON:446440)
South Korea
· Delayed Price · Currency is KRW
12,700
+200 (1.60%)
At close: Aug 14, 2025
Epibiotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2022 | FY 2021 |
| Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -5,058 | -3,195 |
| Depreciation & Amortization | 743.99 | 373.93 |
| Loss (Gain) From Sale of Assets | 38.21 | 15.71 |
| Other Operating Activities | 0 | -30.21 |
| Change in Accounts Receivable | 51.12 | -48.44 |
| Change in Inventory | -23.74 | 2.08 |
| Change in Accounts Payable | - | -21.02 |
| Change in Income Taxes | -0.88 | - |
| Change in Other Net Operating Assets | -175.77 | 79.49 |
| Operating Cash Flow | -4,425 | -2,824 |
| Capital Expenditures | -699.36 | -1,745 |
| Sale (Purchase) of Intangibles | - | -10 |
| Sale (Purchase) of Real Estate | - | -13.59 |
| Investment in Securities | 4,012 | -3,665 |
| Other Investing Activities | -30 | -165.98 |
| Investing Cash Flow | 3,283 | -5,600 |
| Long-Term Debt Repaid | -66.72 | -300 |
| Net Debt Issued (Repaid) | -66.72 | -300 |
| Issuance of Common Stock | 1,543 | 10,220 |
| Other Financing Activities | 60 | - |
| Financing Cash Flow | 1,536 | 9,920 |
| Miscellaneous Cash Flow Adjustments | -0 | -0 |
| Net Cash Flow | 393.92 | 1,496 |
| Free Cash Flow | -5,124 | -4,569 |
| Free Cash Flow Margin | -1139.68% | -1177.98% |
| Free Cash Flow Per Share | -3004.95 | -2695.24 |
| Levered Free Cash Flow | -2,490 | - |
| Unlevered Free Cash Flow | -2,433 | - |
| Change in Working Capital | -149.26 | 12.11 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.